A study to determine clinical characteristics and outcome of patients with cerebral venous sinus thrombosis after SARS-CoV-2 vaccination with and without Thrombosis with thrombocytopenia syndrome
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 08 Oct 2021 New trial record
- 28 Sep 2021 Results published in the JAMA Neurology